WO2001007023A3 - Azetidine compounds in cns and eye diseases - Google Patents

Azetidine compounds in cns and eye diseases Download PDF

Info

Publication number
WO2001007023A3
WO2001007023A3 PCT/GB2000/002841 GB0002841W WO0107023A3 WO 2001007023 A3 WO2001007023 A3 WO 2001007023A3 GB 0002841 W GB0002841 W GB 0002841W WO 0107023 A3 WO0107023 A3 WO 0107023A3
Authority
WO
WIPO (PCT)
Prior art keywords
eye diseases
cns
azetidine compounds
aryl
alkyl
Prior art date
Application number
PCT/GB2000/002841
Other languages
French (fr)
Other versions
WO2001007023A2 (en
Inventor
Mike Snape
Nathaniel Julius Monck
Allan Fletcher
Kelly Jean Stanhope
Howard Langham Mansell
Alan John Nelson
Original Assignee
Vernalis Res Ltd
Mike Snape
Nathaniel Julius Monck
Allan Fletcher
Kelly Jean Stanhope
Howard Langham Mansell
Alan John Nelson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd, Mike Snape, Nathaniel Julius Monck, Allan Fletcher, Kelly Jean Stanhope, Howard Langham Mansell, Alan John Nelson filed Critical Vernalis Res Ltd
Priority to EP00946208A priority Critical patent/EP1212054A2/en
Priority to AU60080/00A priority patent/AU6008000A/en
Priority to JP2001511909A priority patent/JP2003505414A/en
Publication of WO2001007023A2 publication Critical patent/WO2001007023A2/en
Publication of WO2001007023A3 publication Critical patent/WO2001007023A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Use of a compound of formula (I) wherein: R1 is aryl; R2 is H, alkyl or aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
PCT/GB2000/002841 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases WO2001007023A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00946208A EP1212054A2 (en) 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases
AU60080/00A AU6008000A (en) 1999-07-23 2000-07-21 Chemical compounds-ii
JP2001511909A JP2003505414A (en) 1999-07-23 2000-07-21 Azetidine compounds in CNA and eye diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9917386.6A GB9917386D0 (en) 1999-07-23 1999-07-23 Chemical compounds-II
GB9917386.6 1999-07-23

Publications (2)

Publication Number Publication Date
WO2001007023A2 WO2001007023A2 (en) 2001-02-01
WO2001007023A3 true WO2001007023A3 (en) 2001-05-25

Family

ID=10857864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002841 WO2001007023A2 (en) 1999-07-23 2000-07-21 Azetidine compounds in cns and eye diseases

Country Status (5)

Country Link
EP (1) EP1212054A2 (en)
JP (1) JP2003505414A (en)
AU (1) AU6008000A (en)
GB (1) GB9917386D0 (en)
WO (1) WO2001007023A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006525298A (en) * 2003-05-01 2006-11-09 ヴァーナリス リサーチ リミテッド Azetidine carboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders
KR20060017763A (en) * 2003-05-01 2006-02-27 베르날리스 리서치 리미티드 The use of azetidinecarboxamide derivatives in therapy
US20070173486A1 (en) * 2003-05-01 2007-07-26 Vernalis Research Limited Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrs
US11141404B1 (en) 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
WO2023064225A1 (en) 2021-10-11 2023-04-20 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226861A (en) * 1978-04-18 1980-10-07 A. H. Robins Company, Inc. N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
EP0102194A1 (en) * 1982-08-19 1984-03-07 A.H. Robins Company, Incorporated 3-Phenoxy-1-azetidinecarboxamides and their use and preparation
US4505907A (en) * 1982-09-02 1985-03-19 A. H. Robins Company, Inc. N-Formyl and N-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides
EP0194112A1 (en) * 1985-02-28 1986-09-10 A.H. Robins Company, Incorporated 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity
US5095014A (en) * 1990-12-07 1992-03-10 A. H. Robins Company, Incorporated 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity
US5183903A (en) * 1991-11-26 1993-02-02 A. H. Robins Company, Incorporated Urea fusion process for the synthesis of 3-phenoxy-1-azetidinecarboxamides
WO1999037614A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for the treatment of cns disorders
WO1999037612A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
WO2001007043A1 (en) * 1999-07-23 2001-02-01 Vernalis Research Limited Azetidine carboxamide derivatives for the treatment of cns disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226861A (en) * 1978-04-18 1980-10-07 A. H. Robins Company, Inc. N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
CH645352A5 (en) * 1978-04-18 1984-09-28 Robins Co Inc A H N-Lower alkyl-3-phenoxy-1-azetidinecarboxamides
EP0102194A1 (en) * 1982-08-19 1984-03-07 A.H. Robins Company, Incorporated 3-Phenoxy-1-azetidinecarboxamides and their use and preparation
US4505907A (en) * 1982-09-02 1985-03-19 A. H. Robins Company, Inc. N-Formyl and N-hydroxymethyl-3-phenoxy-1-azetidinecarboxamides
EP0194112A1 (en) * 1985-02-28 1986-09-10 A.H. Robins Company, Incorporated 3-Aryl-oxyazetidinecarboxamides having anti-muscle tension, anti-muscle spasticity, anticonvulsant and antiepilectic activity
US5095014A (en) * 1990-12-07 1992-03-10 A. H. Robins Company, Incorporated 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity
US5183903A (en) * 1991-11-26 1993-02-02 A. H. Robins Company, Incorporated Urea fusion process for the synthesis of 3-phenoxy-1-azetidinecarboxamides
WO1999037614A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for the treatment of cns disorders
WO1999037612A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for treating cns disorders
WO2001007043A1 (en) * 1999-07-23 2001-02-01 Vernalis Research Limited Azetidine carboxamide derivatives for the treatment of cns disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAYLOR C R: "ANTICONVULSANT ACTIVITY OF A SERIES OF 3-ARYLOXY-1-AZETIDINE CARBOXAMIDES", AMERICAN CHEMICAL SOCIETY. ABSTRACTS OF PAPERS (AT THE NATIONAL MEETING), AMERICAN CHEMICAL SOCIETY, US, vol. 192, 1 January 1986 (1986-01-01), US, pages 04 - MEDI, XP000987264, ISSN: 0065-7727 *

Also Published As

Publication number Publication date
EP1212054A2 (en) 2002-06-12
AU6008000A (en) 2001-02-13
JP2003505414A (en) 2003-02-12
GB9917386D0 (en) 1999-09-22
WO2001007023A2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
TWI255807B (en) Therapeutic agents
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
NO20055655L (en) Use of azetidinecarboxamide derivatives in therapy
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
WO2004013120A8 (en) Novel benzodioxoles
AU2003284632A1 (en) Isoquinoline compounds and medicinal use thereof
WO2002008219A3 (en) 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
AU5752194A (en) Benzimidazole compounds, their use and preparation
BG106481A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumour agents
IL166412A0 (en) Novel use of benzothiazole derivatives
WO2005012269A8 (en) Novel azole compound
CA2243234A1 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives
IL145005A0 (en) 4-OXO-4, 7-DIHYDRO-THIENO[2,3-b] PYRIDINE-5-CARBOXAMIDES AS ANTIVIRAL AGENTS
MXPA04010055A (en) Thioxanthine derivatives as myeloperoxidase inhibitors.
MXPA05011207A (en) Use of derivatives of 2, 4-dihydro-[1,2,4]triazole-3-thione as inhibitors o fteh enzyme myeloperoxidase (mpo).
EP1142881A4 (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
WO2001007023A3 (en) Azetidine compounds in cns and eye diseases
WO2001007022A3 (en) Azetidine compounds in cns and eye diseases
MXPA04005077A (en) Benzothiazole derivatives.
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
WO1999038841A8 (en) Adamantanecarboximidamide derivatives and their use as nmda antagonists
AU2116900A (en) 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
CA2050875A1 (en) 3-(1h-indazol-3-yl)-4-pyridinamines, a process and intermediates for their preparation and their use as medicaments
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000946208

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000946208

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10031347

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000946208

Country of ref document: EP